VativoRx, LLC

10/28/2025

💊 Pfizer will retire low-dose Vyndaqel® (tafamidis 20mg) by year-end 2025 to simplify treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Higher-dose Vyndamax® (61mg) offers the same benefit in one daily capsule.

https://vativorx.com/pharmacy-bulletin-10-28-2025/

On Aug. 29, 2025, Pfizer announced plans to discontinue Vyndaqel® (tafamidis meglumine 20mg), by the end of 2025.

10/24/2025

Puerto Rico’s hospitals are caught between capped funding, MA-driven reimbursement limits, and workforce strain—yet care demand keeps climbing.

Edition 16 of The Rebate Report breaks down the island’s financial pressures and how strategic rebate management helps build stability when rates can’t rise.

📖 Read now → https://www.linkedin.com/feed/update/urn:li:activity:7387552215953010688

10/10/2025

Two days until SIIA! Meet our team in Phoenix, Oct 12–14, to explore how rebate recovery offsets rising drug costs.

10/09/2025

🚨 FDA withdraws approval of Ixchiq™ (chikungunya vaccine) after reports of serious adverse events, including 3 deaths & 21 hospitalizations linked to vaccine-related illness. Distribution in the U.S. must stop immediately.

https://vativorx.com/pharmacy-bulletin-10-09-2025/

On Aug. 25, 2025, the US Food and Drug Administration (FDA) suspended approval of Ixchiq™ (live attenuated chikungunya virus vaccine - Valneva SE) for adults at an increased risk of exposure to the chikungunya virus, a mosquito-borne disease that can cause debilitating joint pain, fever and rash.

10/08/2025

Reimbursement volatility is reshaping hospital and outpatient economics. But forward-thinking infusion centers are finding strength where others see loss, by turning compliant rebate capture into a financial safety net.

In this edition of The Rebate Report, we explore how even a small percentage of verified, Part B claims can deliver a six-figure impact, and why that precision matters more than volume.

How is your organization planning for reimbursement stability in 2025?

Read Edition 15: https://www.linkedin.com/pulse/reimbursement-headwinds-rise-revenue-resilience-vativorx-llc-5jtce

Please share your perspective below; we may feature your insight in the next issue.

Hospitals, infusion centers, and outpatient facilities are feeling the squeeze. Payment caps, shifting site-of-care policies, and biosimilar pricing fluctuations have made consistent reimbursement harder to maintain in 2025.

10/06/2025

We’re excited to announce that VativoRx and Cooperton will be exhibiting together at the Puerto Rico Hospital Association Conference, October 30–31, 2025, in San Juan, PR.

You’ll find us at Booths #78 & #79, where we’ve created a shared lounge space designed for real conversations with hospital leaders across the island.

Puerto Rico’s healthcare systems face increasing pressure, from rising drug costs to growing cybersecurity risks. Together, VativoRx and Cooperton are helping hospitals build financial and operational resilience through:

* Smarter rebate recovery and hidden revenue optimization.
* Trusted cybersecurity and technology solutions for critical infrastructure.

We look forward to connecting with executives, clinicians, and administrators to explore how innovation, compliance, and partnership can strengthen Puerto Rico’s healthcare ecosystem.

See you at PRHA 2025!

10/02/2025

We’re headed to Phoenix for the SIIA National Conference, Oct 12–14!

VativoRx will be connecting with self-insured healthcare organizations, TPAs, and workers’ comp leaders to address one of the toughest challenges in the industry: specialty drug costs.

We look forward to valuable conversations and new partnerships at this important event.

09/26/2025

🚨 FDA approves Tonmya™ (cyclobenzaprine sublingual) for adults with fibromyalgia. A new nightly treatment that targets poor sleep, one of the root drivers of pain, showed improvements in pain, fatigue & sleep disturbance.

https://vativorx.com/pharmacy-bulletin-09-26-2025/

On Aug. 15, 2025, the US Food and Drug Administration (FDA) approved Tonix Pharmaceuticals’ Tonmya™ (cyclobenzaprine hydrochloride) sublingual tablets for the treatment of fibromyalgia in adults. Fibromyalgia is a chronic pain disorder affecting over 10 million American adults, primarily women.

09/22/2025

🚨 FDA update: Skysona® (gene therapy for cerebral adrenoleukodystrophy) now restricted to boys w/ no matched stem cell donor after 15% of trial patients developed blood cancers, including 1 death. Lifelong cancer monitoring required.

https://vativorx.com/pharmacy-bulletin-09-22-2025/

On Aug. 8, 2025, the US Food and Drug Administration (FDA) restricted Bluebird Bio’s Skysona® (elivaldogene autotemcel) following reports of blood cancers. Skysona is a one-time gene therapy for cerebral adrenoleukodystrophy (CALD), a rare genetic disorder, approved for boys aged four years to 17...

09/19/2025

Self-funded employers know rebates matter.

But here’s the catch: while most capture pharmacy benefit rebates, medical rebates from high-cost infused or physician-administered drugs often go unclaimed.

For self-funded plans, that means:
⚠️ Lost dollars that belong to the plan
⚠️ Missed opportunities to reinvest in employees
⚠️ A distorted view of true healthcare costs

In this edition of The Rebate Report, we explore how strategic rebate management helps employers close the gap, without disrupting PBM or specialty pharmacy relationships.

💬 Are you confident you’re capturing every rebate dollar available to your plan?

👉 Read Edition 14 here: https://www.linkedin.com/pulse/rebate-dollars-self-funded-employers-often-miss-vativorx-llc-hvw0e

Self-funded employers have long understood the power of rebates. Pharmacy benefit rebates are often built into plan financing and projected savings.

09/16/2025

🚨 FDA expands approval for Ajovy® (fremanezumab)!

Now approved to prevent episodic migraines in kids & teens (6–17 yrs, 45kg+)
First & only CGRP blocker for pediatric migraine prevention
Once-monthly injection, at home or in office

https://vativorx.com/pharmacy-bulletin-09-16-2025/

On Aug. 6, 2025, the US Food and Drug Administration (FDA) approved Teva Pharmaceuticals’ Ajovy® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged six years to 17 years weighing 45kg or more.

09/08/2025

🚨 FDA approves Ascendis Pharma’s Skytrofa® (lonapegsomatropin) for adult growth hormone deficiency (GHD).

✅ Once-weekly injection with sustained release
✅ Already approved for pediatric GHD (since 2021)
✅ May improve treatment adherence

https://vativorx.com/pharmacy-bulletin-09-08-2025/

On July 28, 2025, the US Food and Drug Administration (FDA) granted Ascendis Pharma approval of Skytrofa® (lonapegsomatropin-tcgd), a long-acting prodrug of human growth hormone, for the treatment of adult growth hormone deficiency (GHD). Initially approved in 2021 for pediatric GHD, Skytrofa uses ...